MicroRNA 9-3p Targets β(1) Integrin To Sensitize Claudin-Low Breast Cancer Cells to MEK Inhibition

Por Zawistowski, Jon S., Nakamura, Kazuhiro, Parker, Joel S., Granger, Deborah A., Golitz, Brian T., Johnson, Gary L.
Publicado em 2013

SWI/SNF Chromatin-Remodeling Factor Smarcd3/Baf60c Controls Epithelial-Mesenchymal Transition by Inducing Wnt5a Signaling

Por Jordan, Nicole Vincent, Prat, Aleix, Abell, Amy N., Zawistowski, Jon S., Sciaky, Noah, Karginova, Olga A., Zhou, Bingying, Golitz, Brian T., Perou, Charles M., Johnson, Gary L.
Publicado em 2013

PARC/CUL9 Mediates the Degradation of Mitochondrial-released Cytochrome c and Promotes Survival in Neurons and Cancer Cells

Por Gama, Vivian, Swahari, Vijay, Schafer, Johanna, Kole, Adam J., Evans, Allyson, Huang, Yolanda, Cliffe, Anna, Golitz, Brian, Sciaky, Noah, Pei, Xin-Hai, Xiong, Yue, Deshmukh, Mohanish
Publicado em 2014

GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer.

Por Bevill, Samantha M., Olivares-Quintero, Jose F., Sciaky, Noah, Golitz, Brian T., Singh, Darshan, Beltran, Adriana S., Rashid, Naim U., Stuhlmiller, Timothy J., Hale, Andrew, Moorman, Nathaniel J., Santos, Charlene M., Angus, Steven P., Zawistowski, Jon S., Johnson, Gary L.
Publicado no Mol Cancer Res (2019)

TMIC-25. DISSECTING THE ROLE OF HOST GENETICS IN GLIOMA EVOLUTION USING GENETICALLY-ENGINEERED MOUSE MODELS AND THE COLLABORATIVE CROSS

Por Skinner, Kasey, Ferris, Martin, Bash, Ryan, Shelton, Abigail, Smithberger, Erin, Angus, Steven, Golitz, Brian, Sciacky, Noah, Simon, Jeremy, Stein, Jason, Matsushima, Glenn, Ostrom, Quinn, Stetson, Lindsay, Barnholtz-Sloan, Jill, Dhruv, Harshil, Berens, Michael, de Villena, Fernando Pardo Manuel, Miller, Ryan
Publicado no Neuro Oncol (2018)

Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy

Por Lipner, Matthew B., Peng, Xianlu L., Jin, Chong, Xu, Yi, Gao, Yanzhe, East, Michael P., Rashid, Naim U., Moffitt, Richard A., Herrera Loeza, Silvia G., Morrison, Ashley B., Golitz, Brian T., Vaziri, Cyrus, Graves, Lee M., Johnson, Gary L., Yeh, Jen Jen
Publicado no JCI Insight (2020)

Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer

Por Van Swearingen, Amanda E D, Sambade, Maria J, Siegel, Marni B, Sud, Shivani, McNeill, Robert S, Bevill, Samantha M, Chen, Xin, Bash, Ryan E, Mounsey, Louisa, Golitz, Brian T, Santos, Charlene, Deal, Allison, Parker, Joel S, Rashid, Naim, Miller, C Ryan, Johnson, Gary L, Anders, Carey K
Publicado no Neuro Oncol (2017)

Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth

Por Krulikas, Linas J., McDonald, Ian M., Lee, Benjamin, Okumu, Denis O., East, Michael P., Gilbert, Thomas S. K., Herring, Laura E., Golitz, Brian T., Wells, Carrow I., Axtman, Allison D., Zuercher, William J., Willson, Timothy M., Kireev, Dmitri, Yeh, Jen Jen, Johnson, Gary L., Baines, Antonio T., Graves, Lee M.
Publicado no SLAS Discov (2018)

Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex

Por Zawistowski, Jon S., Bevill, Samantha M., Goulet, Daniel R., Stuhlmiller, Timothy J., Beltran, Adriana S., Olivares-Quintero, Jose F., Singh, Darshan, Sciaky, Noah, Parker, Joel S., Rashid, Naim U., Chen, Xin, Duncan, James S., Whittle, Martin C., Angus, Steven P., Velarde, Sara Hanna, Golitz, Brian T., He, Xiaping, Santos, Charlene, Darr, David B., Gallagher, Kristalyn, Graves, Lee M., Perou, Charles M., Carey, Lisa A., Earp, H. Shelton, Johnson, Gary L.
Publicado no Cancer Discov (2017)